Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries

Borrello,Ivan Marques; Schaffer,Madeline Mag; Roehrl,Elena; Marshall,Jessica Falco

doi:10.3892/mco.2014.242

March-April 2014 Volume 2 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-April 2014 Volume 2 Issue 2

Full Size Image

Article

Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries

Authors:
- Ivan Marques Borrello
- Madeline Mag Schaffer
- Elena Roehrl
- Jessica Falco Marshall
View Affiliations / Copyright

Affiliations: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA, European Institute for Medical and Scientific Education, 1010 Vienna, Austria, Advanced Studies in Medicine, Somerville, NJ 08876, USA
Pages: 269-274
|
Published online on: January 14, 2014

https://doi.org/10.3892/mco.2014.242
Expand metrics +

Abstract

The treatment of cancer has changed significantly over the past decade, from a treatment paradigm based primarily on surgery, chemotherapy and radiotherapy, to the development of targeted therapies involving tumor‑specific signaling pathways, as well as the immune system. Recent developments have demonstrated the significant clinical benefits of immunotherapy that are quickly being established as standard treatments for certain malignancies. In this study, we demonstrated that clinical practice is not keeping pace with advancing immuno‑oncology principles and research. We further demonstrated that the incorporation of immunotherapeutic approaches into the treatment of cancer patients varies widely, not only between developed and developing countries, but also between countries in specific geographical areas that have experienced similar cultural and economic development. We developed a survey to assess the deficiencies in scientific understanding, access to information and treatment options and investigated the differences in clinical practice behaviors among oncologists from six European countries: France, Germany, Greece, Italy, Spain and the United Kingdom. Our data demonstrated significant differences in all the categories assessed. Therefore, we concluded that there is a need to develop similar assessment tools to identify care imbalances, so that initiatives may be developed to correct care inequities that ultimately affect patient outcomes worldwide.

View Figures

View References

1	DeVita VT Jr and Rosenberg SA: Two hundred years of cancer research. N Engl J Med. 366:2207–2214. 2012.PubMed/NCBI
2	US Department of Health and Human Services. First monoclonal antibody approved to treat cancer [press release]. November 26–1997, http://archive.hhs.gov/news/press/1997pres/971126.html. accessed June 17, 2013
3	Boyiadzis M and Foon KA: Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 8:1151–1158. 2008. View Article : Google Scholar
4	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
5	Finn OJ: Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 23:viii6–viii9. 2012.PubMed/NCBI
6	Hoos A and Britten CM: The immuno-oncology framework: enabling a new era of cancer therapy. Oncoimmunology. 1:334–339. 2012. View Article : Google Scholar : PubMed/NCBI
7	Borghaei H, Smith MR and Campbell KS: Immunotherapy of cancer. Eur J Pharmacol. 625:41–54. 2009. View Article : Google Scholar
8	Butterfield LH, Disis ML, Khleif SN, Balwit JM and Marincola FM: Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med. 8:1302010. View Article : Google Scholar : PubMed/NCBI
9	FDA approval letter to Dendreon Corporation. April 29–2010, http://www.fda.gov/BiologicsBloodVaccines/CellulargeneTherapyProducts/ApprovedProducts/ucm210215.htm. accessed June 17, 2013
10	US Department of Health and Human Services, Food and Drug Administration. BLA approval letter, YERVOY (ipilimumab). March 25–2011, http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/125377s000ltr.pdf. accessed June 17, 2013
11	Committee for Medicinal Products for Human Use, European Medicines Agency. Assessment Report for Yervoy (ipilimumab). Procedure number: EMEA/H/C/002213. May 19–2011, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002213/WC500109302.pdf. accessed June 17, 2013
12	Abdel-Wahab M, Alfonso R, Anacak Y, et al: Human Health Reports No. 3: Inequity in cancer care: a global perspective. International Atomic Energy Agency; Vienna, Austria: pp. 1–51. 2011
13	Casali PG: Medical oncology: the long-awaited prize of recognition. Ann Oncol. 8:1695–1697. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wolchok JD, Hoos A, O’Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
15	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). EJC. 45:228–247. 2009. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries

This article is mentioned in:

Abstract

Figure 1

Related Articles